Cardiovascular
Welcome to MassDevice's Cardiovascular Hub, your resource for the latest news in cardiac implants, structural heart, heart valves, stents and more. Stay informed about the innovations and business news shaping the cardiovascular device industry.
🫀 Narrow your focus with these categories:
Cardiac Implants | Structural Heart | Pulsed-Field Ablation
Here are top cardiology features from MassDevice and its sister publications (and scroll down to read the latest cardiology device news from MassDevice):
+ LVADs save lives: So why aren’t more available?
+ How Medtronic uses nitinol to improve the structure and effectiveness of heart devices
+ How Abbott designed the world’s first dual-chamber leadless pacemaker system
+ J&J used RWE for expanded indications — and you can, too
+ 7 cardiology startups you need to know
Latest Cardiology News
Israel-based Keystone Heart raises $14M for cerebral protection
Israeli device maker Keystone Heart raised $14 million in a Series B funding round in support of its TriGaurd implant, designed to help protect the brain during transcatheter valve replacement procedures.
Medicare proposes to cover Abbott’s MitraClip heart valve repair device
Medicare today proposed to cover surgeries to fix or replace leaky heart valves called transcatheter mitral valve procedures, issuing a draft National Coverage Decision for the procedure.
TAVI: St. Jude implants 1st patients in U.S. Portico study
Minnesota medtech maker St. Jude Medical (NYSE:STJ) launched a U.S. study of its Portico catheter-based aortic valve, enrolling the 1st patients in pursuit of FDA approval for the implant.
HRS2014: Perforations, deaths temporarily derail St. Jude’s E.U. Nanostim study
Updated May 12, 2014, at 5:30 p.m. with confirmation from St. Jude Medical.
HRS2014: St. Jude Medical and the ghost of product recall past
Battery wars at HRS2014: And the winner is?
A string of presentations and poster sessions during this week’s Heart Rhythm conference pitted device makers against each other in the battle for battery superiority.
HRS2014: Boston Scientific’s S-ICD strong at 22 months, promising in post-ICD patients
HRS2014: Medtronic cardiac rhythm implants fail 1st in head-to-head studies of longevity, researchers say
Biosensors lands FDA OK to launch U.S. trial of drug-eluting stent
Promus Premier stent debuts in Japan
Medtech titan Boston Scientific (NYSE:BSX) has launched commercial efforts after landing Japanese regulatory approval for its Promus Premier drug-eluting stent.